A Phase Ib Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Carcinoma

ID Number 14-0277

Principal Investigator(s)
Celina Ang

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to test the safety of an experimental drug, OMP-54F28, when combined with sorafenib that is standard treatment for hepatocellular cancer. “Experimental” means that the study drug has not been approved by the U.S. Food and Drug Administration (FDA) for use outside research studies. This study is designed to test the safety of the study drug at different dose levels and the effects, both good and bad, that it has on you and your cancer when combined with sorafenib. Since the study drug has not been tested with sorafenib in humans before, it is not known if it will benefit to you and if it will cause harmful side effects.


Many cancer drugs often shrink tumors at first but may not have long-term benefits. One possible explanation for this is that these drugs do not affect specific cancer cells called “cancer stem cells”. Cancer stem cells make up a small fraction of tumor cells, are more resistant to chemotherapy and radiation, and cause tumor regrowth and spread. The study drug blocks the growth of cancer stem cells and may help other cancer drugs, such as sorafenib, be more effective.

Contact Information
(212) 824-7309

Recruiting Patients: No